The Indian Pharma market registered a growth of 7.8 per cent during December 2017 to Rs. 10,000 crore. The growth of the market is slightly lower than last month.
According to AIOCD Pharmasofttech AWACS report, the volumes have posted a positive growth, however price component is dragging the market. FDC related market showed growth of 4 per cent while the Non FDC market showed a growth of 8.7 per cent while the single molecules grew at 7.1 per cent for the month Dec 17. MNCs are growing at 6.3 per cent for Dec-17, while Indian companies are growing faster at 8.2 per cent.
Anti-infectives are showing good growth for Dec-2017 (8.2 per cent), while Dermatology posted slightly lower growth than the double digits. Respiratory segment showed healthy double digit growth of 14.9 per cent. Gastro intestinal has shown a positive turnaround this month and is growing at 7.6 per cent while Vitamins are also showing at positive growth (6.5 per cent) for the month of Dec-17. Major Chronic therapy like Anti-diabetic posted a double digit growth (10.4 per cent). Cardio segment has posted single digit growth for the month (4.4 per cent), CNS is also growing better as compared to last month (8.4 per cent). Only derma (11.2 per cent) and anti-diabetics (12.3 per cent) segment are showing a double digit growth in the period of Apr-Dec-17 amongst the top 10 segments.
Amongst the top 10 corporate, Mankind has the highest growth at 19.9 per cent followed by Lupin at 12.9 per cent and Alkem at 12.4 per cent. 40 corporate showing positive growth of IPM for the month of Dec-17 amongst top 50. Amongst the top 50 corporate Hetero has the highest growth of 38.8 per cent followed by Allergan growing at 34.9 per cent and La Renon growing at 28.5 per cent.
The Apr-Dec -17 growth for the industry is 4.9 per cent. Clearly showing the impact of the run-up to GST and implementation of GST. Dec-17 Qtr saw a better volume growth at 5.9 per cent & Price Growth at – 1.5 per cent while the new products fared comparatively better at 2.8 per cent.
Abbott HC is growing slower than (4.7 per cent) and Abbott India (11.4 per cent) for Dec-17. Sun Portfolio has shown double digit growth 11.9 per cent, while Ranbaxy slowed down with a growth of 1.6 per cent for the month of Dec-17. Total 23 companies launched in last 36 Months and one company cross Rs. 10 crore in revenue.
Amongst the top 60 MNCs, Allergan was the fastest growing at 34.9 per cent followed by Eli Lilly growing at 20.9 per cent and Boehringer Ingelheim which grew at 14.3 per cent for Dec-17. In the Non-NLEM category Indian companies showed a growth of 9.2 per cent whereas MNCs grew at 6.9 per cent. The NLEM 2013 containing molecules market showed growth at 3 per cent whereas the non NLEM market grew at 8.7 per cent resulting in an overall growth of 7.8 per cent for the month of Dec 2017.
From therapy perspective 17 therapies are showing a positive growth for the month of Dec -17. Respiratory market posted a double growth of 14.9 per cent, Gastro Intestinal is growing at 7.6 per cent and pain and analgesic market showed growth of 6 per cent for Dec-17. Anti-diabetic market is growing at 10.4 per cent & cardiac at 4.4 per cent, Neuro/CNS showed a growth of 8.4 per cent for month Dec -17 amongst the chronic care categories. Anti-malarials degrew at -7.8 per cent & VMS Market is growing at 6.5 per cent. Derma is growing at 9.6 per cent for Dec 2017 slow down as compared to Nov 2017.
From regional perspective 29 regions have posted positive growth for month of Dec-17. UP east market grew the highest at 26.4 per cent followed by North Karnataka growing at 17.4 per cent & Haryana at 15.3 per cent for Dec-17.
Amoxycillin + Clavulanic Acid market is showing a recovery at 10 per cent monthly growth in Dec -17. Glimepiride + Metformin market is stagnant at 0.56 per cent. Glimepiride + Metformin was pegged at Rs. 169.1 crore & Amoxycillin + Clavulanic Acid market pegged at Rs. 160.5 crore. Azilsartan plain market is now valued at Rs. 56.8 crore on mat basis. Sofosbuvir and its combination market has reached Rs. 575.3 crore on mat basis. The Luliconazole market is worth Rs. 233.2 crore on mat basis. While Tenegliptin and its combinations are pegged at Rs. 586.4 crore.
The market of Paracetamol plain is growing at 8.97 per cent on monthly basis, plain Atorvastatin is declining at -5.58 per cent. Probiotic Microbes is showing a double digit growth of 15.28 per cent , Pantoprazole plain has posted a growth of 7.36 per cent, Montelukast + Levocetrizine is growing at a double digit rate of 18.81 per cent , Voglibose + Metformin + Glimepiride has posted a double digit growth of 12.94 per cent, Plain Azithromycin is showing monthly growth of 6.62 per cent
Mixtard leads the pack with Rs. 47 crore followed by Glycomet GP at Rs. 33 crore, Spasmoproxyvon Plus at Rs. 38 crore, Lantus at Rs. 33 crore & Galvus Met at Rs. 33 crore and Liv 52 Rs. 24 crore and Janumet at Rs. 34 crore for Dec-17.
Few Brands who have gained ranks on MAT basis include Novomix (+3), Cilacar (+22), Udiliv (+15), Ultracet (+9), Duolin, (+27), Gluconorm G (+6), Telma H (+4), Allegra (+19), Synflorix (+11), Gemer (+4), Ecosprin AV (+11), Duphaston (+14),Pan D (+5), Istamet (+5).
Azilsartan is a recently launched molecule now valued at Rs. 57 crore. There are 41 brands already launched. On MAT Basis with Zilarbi (Emcure) leading followed by Aztric (Intas) and Abel (Lupin). Luliconazole segment is worth Rs. 233.2 crore on MAT basis there are already 37 brands in the foray. Benidipine molecule and its combinations is now valued at Rs.16.8 crore on MAT Basis with Inzit (Eris) leading followed by Benitowa (Akumentis) and Benipack (Koye). Acotiamide molecule is now valued at Rs. 43 crore on MAT basis with Acogut (Lupin) is leading followed by Actapro (Sun) & Acotrust (DRL). Dulaglutide launched under the brand name Trulicity by Eli Lilly is now valued at Rs.19 crore.
Within the Anti-diabetic category there are 2 brands launched in the month of Dec -17. Within the VMS category there have been 4 brands launched for the month of Dec-17. Within Cardiac there have been 5 brands launched in Dec-17. Within Derma there were 35 brands launched in Dec -17. Within Gastro18 new brands were launched in Dec -17.
According to AIOCD Pharmasofttech AWACS report, the volumes have posted a positive growth, however price component is dragging the market. FDC related market showed growth of 4 per cent while the Non FDC market showed a growth of 8.7 per cent while the single molecules grew at 7.1 per cent for the month Dec 17. MNCs are growing at 6.3 per cent for Dec-17, while Indian companies are growing faster at 8.2 per cent.
Anti-infectives are showing good growth for Dec-2017 (8.2 per cent), while Dermatology posted slightly lower growth than the double digits. Respiratory segment showed healthy double digit growth of 14.9 per cent. Gastro intestinal has shown a positive turnaround this month and is growing at 7.6 per cent while Vitamins are also showing at positive growth (6.5 per cent) for the month of Dec-17. Major Chronic therapy like Anti-diabetic posted a double digit growth (10.4 per cent). Cardio segment has posted single digit growth for the month (4.4 per cent), CNS is also growing better as compared to last month (8.4 per cent). Only derma (11.2 per cent) and anti-diabetics (12.3 per cent) segment are showing a double digit growth in the period of Apr-Dec-17 amongst the top 10 segments.
Amongst the top 10 corporate, Mankind has the highest growth at 19.9 per cent followed by Lupin at 12.9 per cent and Alkem at 12.4 per cent. 40 corporate showing positive growth of IPM for the month of Dec-17 amongst top 50. Amongst the top 50 corporate Hetero has the highest growth of 38.8 per cent followed by Allergan growing at 34.9 per cent and La Renon growing at 28.5 per cent.
The Apr-Dec -17 growth for the industry is 4.9 per cent. Clearly showing the impact of the run-up to GST and implementation of GST. Dec-17 Qtr saw a better volume growth at 5.9 per cent & Price Growth at – 1.5 per cent while the new products fared comparatively better at 2.8 per cent.
Abbott HC is growing slower than (4.7 per cent) and Abbott India (11.4 per cent) for Dec-17. Sun Portfolio has shown double digit growth 11.9 per cent, while Ranbaxy slowed down with a growth of 1.6 per cent for the month of Dec-17. Total 23 companies launched in last 36 Months and one company cross Rs. 10 crore in revenue.
Amongst the top 60 MNCs, Allergan was the fastest growing at 34.9 per cent followed by Eli Lilly growing at 20.9 per cent and Boehringer Ingelheim which grew at 14.3 per cent for Dec-17. In the Non-NLEM category Indian companies showed a growth of 9.2 per cent whereas MNCs grew at 6.9 per cent. The NLEM 2013 containing molecules market showed growth at 3 per cent whereas the non NLEM market grew at 8.7 per cent resulting in an overall growth of 7.8 per cent for the month of Dec 2017.
From therapy perspective 17 therapies are showing a positive growth for the month of Dec -17. Respiratory market posted a double growth of 14.9 per cent, Gastro Intestinal is growing at 7.6 per cent and pain and analgesic market showed growth of 6 per cent for Dec-17. Anti-diabetic market is growing at 10.4 per cent & cardiac at 4.4 per cent, Neuro/CNS showed a growth of 8.4 per cent for month Dec -17 amongst the chronic care categories. Anti-malarials degrew at -7.8 per cent & VMS Market is growing at 6.5 per cent. Derma is growing at 9.6 per cent for Dec 2017 slow down as compared to Nov 2017.
From regional perspective 29 regions have posted positive growth for month of Dec-17. UP east market grew the highest at 26.4 per cent followed by North Karnataka growing at 17.4 per cent & Haryana at 15.3 per cent for Dec-17.
Amoxycillin + Clavulanic Acid market is showing a recovery at 10 per cent monthly growth in Dec -17. Glimepiride + Metformin market is stagnant at 0.56 per cent. Glimepiride + Metformin was pegged at Rs. 169.1 crore & Amoxycillin + Clavulanic Acid market pegged at Rs. 160.5 crore. Azilsartan plain market is now valued at Rs. 56.8 crore on mat basis. Sofosbuvir and its combination market has reached Rs. 575.3 crore on mat basis. The Luliconazole market is worth Rs. 233.2 crore on mat basis. While Tenegliptin and its combinations are pegged at Rs. 586.4 crore.
The market of Paracetamol plain is growing at 8.97 per cent on monthly basis, plain Atorvastatin is declining at -5.58 per cent. Probiotic Microbes is showing a double digit growth of 15.28 per cent , Pantoprazole plain has posted a growth of 7.36 per cent, Montelukast + Levocetrizine is growing at a double digit rate of 18.81 per cent , Voglibose + Metformin + Glimepiride has posted a double digit growth of 12.94 per cent, Plain Azithromycin is showing monthly growth of 6.62 per cent
Mixtard leads the pack with Rs. 47 crore followed by Glycomet GP at Rs. 33 crore, Spasmoproxyvon Plus at Rs. 38 crore, Lantus at Rs. 33 crore & Galvus Met at Rs. 33 crore and Liv 52 Rs. 24 crore and Janumet at Rs. 34 crore for Dec-17.
Few Brands who have gained ranks on MAT basis include Novomix (+3), Cilacar (+22), Udiliv (+15), Ultracet (+9), Duolin, (+27), Gluconorm G (+6), Telma H (+4), Allegra (+19), Synflorix (+11), Gemer (+4), Ecosprin AV (+11), Duphaston (+14),Pan D (+5), Istamet (+5).
Azilsartan is a recently launched molecule now valued at Rs. 57 crore. There are 41 brands already launched. On MAT Basis with Zilarbi (Emcure) leading followed by Aztric (Intas) and Abel (Lupin). Luliconazole segment is worth Rs. 233.2 crore on MAT basis there are already 37 brands in the foray. Benidipine molecule and its combinations is now valued at Rs.16.8 crore on MAT Basis with Inzit (Eris) leading followed by Benitowa (Akumentis) and Benipack (Koye). Acotiamide molecule is now valued at Rs. 43 crore on MAT basis with Acogut (Lupin) is leading followed by Actapro (Sun) & Acotrust (DRL). Dulaglutide launched under the brand name Trulicity by Eli Lilly is now valued at Rs.19 crore.
Within the Anti-diabetic category there are 2 brands launched in the month of Dec -17. Within the VMS category there have been 4 brands launched for the month of Dec-17. Within Cardiac there have been 5 brands launched in Dec-17. Within Derma there were 35 brands launched in Dec -17. Within Gastro18 new brands were launched in Dec -17.